CONTACT INFORMATIONBIOGRAPHYCREDENTIALSAWARDSCLINICAL TRIALSPUBLICATIONSRachael B. Turner, M.D., Ph.D.Contact InformationPhone NumbersAppointment: (585) 442-8020Administrative: (585) 442-8020Office: (585) 442-8020Fax: (585) 442-8039A member of the University of Rochester Medical Faculty GroupgroupAn Accountable Health PartnerassignmentAccepting New PatientsLocationsLattimore Medical Center Oncology125 Lattimore Rd, Ste 258Rochester, NY 14620-4159Oncology: (585) 442-8020Faculty AppointmentsAssistant Professor - Department of Medicine , Hematology/Oncology (SMD) Assistant Professor - Department of Obstetrics and Gynecology (SMD) - JointPatient Care SettingCancerBiographyDr. Rachael Turner received her medical degree and her PhD from the University at Buffalo School of Medicine and Biomedical Sciences in 2013. Dr. Turner then completed her Internal Medicine Residency and Medical Oncology Fellowship at the University of Rochester Medical Center in 2015 and 2018, respectively. She is currently pursuing a Research Fellowship at the University of Rochester Medical Center. Dr. Turner is certified by the American Board of Internal Medicine. Dr. Turner's special interests are women's cancers, including fallopian, ovarian, uterine and cervical. She is also interested in immune therapies for cancer. Dr. Turner is committed to providing personalized cancer care with compassion and dedication. During her free time, Dr. Turner enjoys spending time with her husband and sons, running and hiking.CredentialsSpecialtiesInternal Medicine - American Board of Internal MedicineMedical Oncology - American Board of Internal MedicineEducation2013MD | SUNY State University of New York-Buffalo School of Medicine & Biomedical Sciences (USA)Post-doctoral Training & Residency07/01/2015 - 07/19/2018Fellowship in Medical Oncology at University of Rochester Medical Center07/01/2014 - 06/30/2015Residency in Internal Medicine at University of Rochester Medical Center07/01/2013 - 06/30/2014Internship in Internal Medicine at University of Rochester Medical CenterVIEW ALL expand_moreAwards2020 - 2021Internal Medicine Department Faculty Pilot AwardSponsor: University of RochesterLocation: Rochester, NY2019 - 2020Technology Development Fund GrantSponsor: University of RochesterLocation: Rochester, NY2019 - 2020W.G Stuber Research AwardSponsor: University of RochesterLocation: Rochester, NY2018Wilmot Fellowship AwardSponsor: Wilmot Cancer InstituteLocation: Rochester, NY2018Conquer Cancer Foundation/Women who Conquer Cancer- Young Investigator AwardSponsor: Bristol-Myers SquibbLocation: ASCO2017Best Overall Poster Presentation for HE4 in Ovarian Cancer Immune Suppression Poster PresentationSponsor: James P. Wilmot Cancer InstituteLocation: Rochester, NY2011Harold Brody Award for Translational ResearchSponsor: University of BuffaloLocation: Buffalo, NY2010Honorable Mention for poster presentation on Chronic Chemoimmunotherapy etc..Sponsor: Buffalo ImmunologyLocation: Buffalo, NY2009 - 2011Breast Cancer Pre-doctoral Traineeship AwardSponsor: Department of Defense2005Guy A. Bailey Outstanding Senior AwardSponsor: SUNY GeneseoLocation: Geneseo, NY2005Phi Beta Kappa National Honor Society2004Tri-Beta Honor SocietyVIEW ALL expand_moreClinical TrialsAn Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid TumorsLead Researcher: Rachael B Turner RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy. View Study Details PublicationsJournal Articles2021Rowswell-Turner R; Singh R; Urh A; Yano N; Kim K; Khazan K; Pandita, R; Sivagnanalingam U; Hovanesian V; James N; Ribeiro J; Kadambi S; Linehan D; Moore R. "HE4 Overexpression by ovarian cancer promotes a suppressive tumor immune microenvironment and enhanced tumor and macrophage PD-L1 expression. Published online April 26,2021:" . J Immunol. 2021; .2020Kim KK; Singh RK; Khazan N; Kodza A; Singh NA; Jones A; Sivagnanalingam U; Towner M; Itamochi H; Turner, R; Moore RG. "Development of Potent Forchlorfenurone Analogs and Their Cytotoxic Effect in Cancer Cell Lines." Sci Rep. 2020; 10(1): 3241.2020Kim KK; Turner R; Khazan N; Kodza A; Jones A; Singh RK; Moore RG. "Role of trypsin and protease-active receptor-2 in ovarian cancer." PLOS One. 2020; 15(5): e0232253.VIEW ALL PUBLICATIONSClose WindowSchedule an appointment with Rachael B. Turner, M.D., Ph.D.Please answer the following questions to help us find the right appointment for you.Important: If you believe that you have a medical or psychiatric emergency, please call 911 or go to the nearest hospital. This website is not intended for emergency care.Have you seen this provider in the last 2 years?YesNoExisting Patient Schedule or request a follow up appointment online through MyChart. If you do not have a MyChart account, please close this window and call the appointment phone number. Rachael B. Turner, M.D., Ph.D. is currently scheduling for the following appointment type(s): Our policy does not permit patients to establish care with multiple providers within the same practice or specialty without prior approval. If you choose a new provider in the same office, we will cancel the appointment. Please contact the office directly with questions on this policy.